Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations
Sponsor: Ascenta Therapeutics
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Ascenta Therapeutics
Listed as NCT00988169, this PHASE2 trial focuses on Lung Cancer and remains terminated or withdrawn. Sponsored by Ascenta Therapeutics, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ascenta Therapeutics
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .